Skip to main content
Top
Published in: Journal of Hematopathology 2/2020

01-06-2020 | Primary Myelofibrosis | Letter to the editor

Does the order of mutational acquisition in myeloproliferative neoplasms matter? Evidence from JAK2 exon 12 and DNMT3A co-mutant polycythemia vera

Authors: Rumyana Todorova, Jakob Passweg, Pontus Lundberg, Alexandar Tzankov

Published in: Journal of Hematopathology | Issue 2/2020

Login to get access

Excerpt

Myeloproliferative neoplasms (MPN) have in common an abnormal clonal expansion of differentiated hematopoietic cells in the bone marrow (BM), usually accompanied by excessive production of progenies leading to numeric blood cell increase. Three classical MPN types are recognized—polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). …
Literature
1.
go back to reference Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129:667–679CrossRef Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129:667–679CrossRef
2.
go back to reference Scott LM, Thong W, Levine RL et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459–468CrossRef Scott LM, Thong W, Levine RL et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459–468CrossRef
3.
go back to reference Butcher CM, Hahn U, To LB et al (2008) Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 22:870–873CrossRef Butcher CM, Hahn U, To LB et al (2008) Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 22:870–873CrossRef
4.
go back to reference Barbui T, Thiele J, Gisslinger H et al (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8:15CrossRef Barbui T, Thiele J, Gisslinger H et al (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8:15CrossRef
5.
go back to reference Stegelmann F, Bullinger L, Schlenk RF, Paschka P, Griesshammer M, Blersch C, Kuhn S, Schauer S, Döhner H, Döhner K (2011) DNMT3A mutations in myeloproliferative neoplasms. Leukemia 25:1217–1219CrossRef Stegelmann F, Bullinger L, Schlenk RF, Paschka P, Griesshammer M, Blersch C, Kuhn S, Schauer S, Döhner H, Döhner K (2011) DNMT3A mutations in myeloproliferative neoplasms. Leukemia 25:1217–1219CrossRef
7.
go back to reference Percy MJ, Scott LM, Erber WN, Harrison CN, Reilly JT, Jones FG, Green AR, McMullin M (2007) The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica 92:1607–1614CrossRef Percy MJ, Scott LM, Erber WN, Harrison CN, Reilly JT, Jones FG, Green AR, McMullin M (2007) The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica 92:1607–1614CrossRef
8.
go back to reference Jacquelin S, Straube J, Cooper L, Vu T, Song A, Bywater M, Baxter E, Heidecker M, Wackrow B, Porter A, Ling V, Green J, Austin R, Kazakoff S, Waddell N, Hesson LB, Pimanda JE, Stegelmann F, Bullinger L, Döhner K, Rampal RK, Heckl D, Hill GR, Lane SW (2018) Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. Blood 132:2707–2721CrossRef Jacquelin S, Straube J, Cooper L, Vu T, Song A, Bywater M, Baxter E, Heidecker M, Wackrow B, Porter A, Ling V, Green J, Austin R, Kazakoff S, Waddell N, Hesson LB, Pimanda JE, Stegelmann F, Bullinger L, Döhner K, Rampal RK, Heckl D, Hill GR, Lane SW (2018) Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. Blood 132:2707–2721CrossRef
9.
go back to reference Nangalia J, Nice FL, Wedge DC, Godfrey AL, Grinfeld J, Thakker C, Massie CE, Baxter J, Sewell D, Silber Y, Campbell PJ, Green AR (2015) DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica 100:e438–e442CrossRef Nangalia J, Nice FL, Wedge DC, Godfrey AL, Grinfeld J, Thakker C, Massie CE, Baxter J, Sewell D, Silber Y, Campbell PJ, Green AR (2015) DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica 100:e438–e442CrossRef
Metadata
Title
Does the order of mutational acquisition in myeloproliferative neoplasms matter? Evidence from JAK2 exon 12 and DNMT3A co-mutant polycythemia vera
Authors
Rumyana Todorova
Jakob Passweg
Pontus Lundberg
Alexandar Tzankov
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Published in
Journal of Hematopathology / Issue 2/2020
Print ISSN: 1868-9256
Electronic ISSN: 1865-5785
DOI
https://doi.org/10.1007/s12308-020-00392-x

Other articles of this Issue 2/2020

Journal of Hematopathology 2/2020 Go to the issue